• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»refractory mesial temporal lobe epilepsy

Why AMT-260’s early epilepsy data could shape the next test for brain-delivered gene therapy

By Soujanya Ravi on June 19, 2026   Pharma & Biotech  

Why AMT-260’s early epilepsy data could shape the next test for brain-delivered gene therapy

Find out how uniQure’s AMT-260 early epilepsy data could shape the next test for brain-delivered gene therapy.

Recent Posts

  • Why Premier Biotech’s NexScreen and TransMed acquisitions could reshape rapid drug testing
  • Chai Discovery tests a new commercial route for AI-designed biologics through Lilly TuneLab
  • Why Veraxa Biotech stock fell 23% after its BiTAC-ADC proof-of-concept data
  • Greenstone Biosciences and Intel chase faster drug discovery as regulators back human-relevant models
  • Why AngioDynamics stock investors should watch NanoKnife’s move into benign prostate disease
  • Canada’s healthcare market faces a turning point as Alberta prepares dual-practice surgery launch
  • AbbVie nears reported $10.9bn Apogee deal as zumilokibart heads toward Phase 3
  • Memo Therapeutics advances potravitug as the race for the first BK virus therapy intensifies
  • CureGene targets clopidogrel variability as evategrel begins a critical United States study
  • GSK and Spero win Utebzi approval after an earlier FDA rejection and new Phase 3 trial
  • Can uniQure turn the FDA’s AMT-130 reversal into a Huntington’s disease approval?
  • Replicate Bioscience wins Gates Foundation support for an ambitious TB vaccine strategy
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes